Alpha Tau Medical Ltd.

NASDAQ:DRTS

Biotechnology

Healthcare
$12.01 +0.42%

+$0.04 today

Market cap
$1.11B
Beta
1.20
P/E (TTM)
-15.2
EPS (TTM)
-$0.63
52W Low $2.85High $11.62

Volume 0.64M

Average 0.69M

DRTS Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Alpha Tau Medical Ltd.NASDAQ: DRTS

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $10.98M rose 53.1% year over year, ahead of the +29.3% change in trailing-twelve-month research & development. Sequentially, it rose 14.6% from the prior quarter. Over 3 fiscal years it compounded at +13.9% a year.

Context

  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +53.1% holds above the trailing-twelve-month pace of +29.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$10.98M+14.6% QoQ
Last fiscal yearDec 2025
$30.83M+14.1% YoY
LTMMar 2026
$35.87M+29.3% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+53.1%——
1 year+14.1%——
3-year CAGR+13.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
30.83M USD
Year-over-year change
+14.1%
4-year CAGR
+28.1%

Research & Development vs competitors

How DRTS compares with its peers on the latest reported figures

  • DRTS's LTM Mar 2026 research & development of $35.87M is the lowest of the 3 companies compared; the peer median is $76.57M.
  • Its year-over-year change of +29.3% is the lowest of 3, against a peer median of +70.6%.
  • Over three fiscal years its annual growth of +13.9% compares with a peer median of +143.2%.
DRTS Competitors Peer median
Research & Development for DRTS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CATXPerspective Therapeutics, Inc.LTM Mar 2026$85.68M +76.6%+218.7%13864.6%
AKTSAktis Oncology, Inc.FY2025$67.45M +64.7%+67.7%1038.2%
DRTSAlpha Tau Medical Ltd.LTM Mar 2026$35.87M +29.3%+13.9%—
Peer median (excluding DRTS) $76.57M+70.6%+143.2%7451.4%

Competitors are the stored peer set for DRTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue776K979K1.07M1.1M1.23M
Gross Profit(776K)(979K)(1.07M)(1.1M)(1.23M)
Gross Margin—————
Research & Development11.45M20.89M26.42M27.02M30.83M
Selling, General & Admin2.34M11.25M9.26M7.92M10.22M
Operating Expenses13.79M32.14M34.61M34.94M41.06M
Depreciation & Amortization776K979K1.07M1.1M1.23M
EBITDA(13.22M)(32.74M)(28.03M)(30.3M)(41.06M)
EBITDA Margin—————
Operating Income(13.79M)(32.14M)35.68M(36.04M)(42.29M)
Operating Margin—————
Interest Income211K1.79M4.76M4.28M3.84M
Interest Expense13.27M1.77M39K344K419K
Other Income / Expenses(13.47M)(1.61M)6.54M4.3M(218K)
Income Before Tax(27.26M)(33.74M)(29.14M)(31.74M)(42.51M)
Pre-Tax Margin—————
Income Tax Expense7K20K16K6K121K
Net Income(27.27M)(33.76M)(29.16M)(31.75M)(42.63M)
Net Margin—————
EPS (Basic)(0.67)(0.53)(0.42)(0.45)(0.53)
EPS (Diluted)(0.67)(0.53)(0.42)(0.45)(0.53)
Weighted Avg Shares40.53M63.53M69.38M69.93M80.58M
Weighted Avg Shares (Diluted)40.53M63.53M69.38M69.93M80.58M

Alpha Tau Medical Ltd.

NASDAQ:DRTS

Intrinsic Alpha fair value

Locked

Current Price

$12.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.